VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum

Molecular Therapy

Volumn 2, Issue 3, 2000, Pages 218-222

  DePolo, Nicholas J ^a   Reed, Joyce D ^a   Sheridan, Philip L ^a   Townsend, Kay ^a   Sauter, Sybille L ^a   Jolly, Douglas J ^a   Dubensky Jr , Thomas W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Complement; Human sera inactivation; Lentivirus vector; Resistance; Retroviral vector; VSV G pseudotyping

Indexed keywords

ANIMALIA; FELINE IMMUNODEFICIENCY VIRUS; LENTIVIRUS;

ANTIVIRUS AGENT;

ANIMAL; ARTICLE; BLOOD; CELL LINE; GENE VECTOR; GENETICS; HAMSTER; HUMAN; LENTIVIRINAE; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; BLOOD; CELL LINE; CRICETINAE; GENETIC VECTORS; HUMANS; LENTIVIRUS; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 0034264613     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0116     Document Type: Article

References (37)

1. Cosset, F. L., Takeuchi, Y., Battini, J. L., Weiss, R. A., and Collins, M. K. (1995). High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69: 7430-7436.
2. DePolo, N. J., et al. (1999). The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73: 6708-6714.
3. Pensiero, M. N., Wysocki, C. A., Nader, K., and Kikuchi, G. E. (1996). Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum. GeneTher. 7: 1095-1101.
4. Rigg, R. J., Chen, J., Dando, J. S. Forestell, S. P., Plavec, I., and Bohnlein, E. (1996). A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety. Virology 218: 290-295.
5. Amado, R. G., and Chen, I. S. (1999). Lentiviral vectors - The promise of gene therapy within reach? Science 285: 674-676.
6. Buchschacher, G. L., Jr., and Panganiban, A. T. (1992). Human immunodeficiency virus vectors for inducible expression of foreign genes. J. Virol. 66: 2731-2739.
7. Gasmi, M., Glynn, J., Jin, M. J., Jolly, D. J., Yee, J. K., and Chen, S. T. (1999). Requirements for efficient production and transduction of human immunodeficiency virus type 1 -based vectors. J. Virol. 73: 1828-1834.
8. He, J., and Landau, N. R. (1995). Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J. Virol. 69: 4587-4592.
9. Johnston, J. C., Gasmi, M., Lim, L. E., Elder, J. H., Yee, J. K., Jolly, D. J., Campbell, K. P., Davidson, B. L., and Sauter, S. L. (1999). Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73: 4991-5000.
10. Klimatcheva, E., Rosenblatt, J. D., and Planelles, V. (1999). Lentiviral vectors and gene therapy. Front Biosci. 4: D481-D496.
11. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
12. Poeschla, E. M., Wong-Staal, F., and Looney, D. J. (1998). Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4: 354-357.
13. Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93: 11382-11388.
14. Takahashi, M., Miyoshi, H., Verma, I. M., and Gage, F. H. (1999). Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer. J. Virol. 73: 7812-7816.
15. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
16. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90: 8033-8037.
17. Yee, J. K., Friedmann, T., and Burns, J. C. (1994). Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 43(Pt. A): 99-112.
18. Takeuchi, Y., Cosset, F. L., Lachmann, P. J., Okada, H., Weiss, R. A., and Collins, M. K. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol. 68: 8001-8007.
19. Rother, R. P., Fodor, W. L., Springhorn, J. P., Birks, C. W., Setter, E., Sandrin, M. S., Squinto, S. P., and Rollins, S. A. (1995). A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. 182: 1345-1355.
20. Rother, R. P., and Squinto, S. P. (1996). The alpha-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable. Cell 86: 185-188.
21. Takeuchi, Y., Porter, C. D., Strahan, K. M., Preece, A. F., Gustafsson, K., Cosset, F. L., Weiss, R. A., and Collins, M. K. (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3)galactosyltransferase. Nature 379: 85-88.
22. Mason, J., Guzowski, D., Goodwin, L., Porti, D., Cronin, K., Teichberg, S., and Pergolizzi, R. (1999). Human serum-resistant retroviral vector particles from galactosyl (alpha1-3)galactosyl containing nonprimate cell lines. Gene Ther. 6: 1397-1405.
23. Greengard, J. S., and Jolly, D. J. (1999). Animal testing of retroviral-mediated gene therapy for factor VIII deficiency. Thromb. Haemost. 82: 555.
24. Bowles, N. E., Eisensmith, R. C., Mohuiddin, R., Pyron, M., and Woo, S. L. (1996). A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum. Gene Ther. 7: 1735-1742.
25. DePolo, N. J., Giachetti, C., and Holland, J. J. (1987). Continuing coevolution of virus and defective interfering particles and of viral genome sequences during undiluted passages: Virus mutants exhibiting nearly complete resistance to formerly dominant defective interfering particles. J. Virol. 61: 454-464.
26. Beebe, D. P., and Cooper, N. R. (1981). Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126: 1562-1568.
27. Welsh, R. M., O'Donnell, C. L., Reed, D. J., and Rother, R. P. (1998). Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J. Virol. 72: 4650-4656.
28. Thiry, L., Cogniaux-Le Clerc, J., Content, J., and Tack, L. (1978). Factors which influence inactivation of vesicular stomatitis virus by fresh human serum. Virology 87: 384-393.
29. Takeuchi, Y., Liong, S. H., Bieniasz, P. D., Jager, U., Porter, C. D., Friedman, T., McClure, M. O., and Weiss, R. A. (1997). Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation. J. Virol. 71: 6174-6178.
30. Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93: 11400-11406.
31. Ochsenbein, A. F., Fehr, T., Lutz, C., Suter, M., Brombacher, F., Hengartner, H., and Zinkernagel, R. M. (1999). Control of early viral and bacterial distribution and disease by natural antibodies. Science 286: 2156-2159.
32. Russell, D. W., Berger, M. S., and Miller, A. D. (1995). The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 6: 635-641.
33. Morgan, B. P., and Meri, S. (1994). Membrane proteins that protect against complement lysis. Semin. Immunopathol. 15: 397-416.
34. Montefiori, D. C., Cornell, R. J., Zhou, J. Y., Zhou, J. T., Hirsch, V. M., and Johnson, P. R. (1994). Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205: 82-92.
35. Saifuddin, M., Parker, C. J., Peeples, M. E., Gorny, M. K., Zolla-Pazner, S., Ghassemi, M., Rooney, I. A., Atkinson, J. P., and Spear, G. T. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182: 501-509.
36. Saifuddin, M., Hedayati, T., Atkinson, J. P., Holguin, M. H., Parker, C. J., and Spear, G. T. (1997). Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. J. Gen. Virol. 78: 1907-1911.
37. Spitzer, D., Hauser, H., and Wirth, D. (1999). Complement-protected amphotropic retroviruses from murine packaging cells. Hum. Gene Ther. 10: 1893-1902.